IRadimed Corporation provided revenue guidance for the fourth quarter and full year of 2017. For the quarter, the company expected revenue to $6.7 million. For the year 2017, the company expected revenue of approximately $23.1 million. The company provided earnings guidance for the first quarter and full year of 2018. For the quarter, the company reported revenue of $6.8 million to $6.9 million, GAAP diluted earnings per share of $0.04 to $0.05 and non-GAAP diluted earnings per share of $0.06 to $0.07. Non-GAAP earnings per share guidance excludes stock-based compensation expense, net of tax, which the company expects to be approximately $0.3 million. For the year 2018, the company reported revenue of $29.3 million to $30.0 million, GAAP diluted earnings per share of $0.22 to $0.27 and non-GAAP diluted earnings per share of $0.33 to $0.38. Non-GAAP earnings per share guidance excludes stock-based compensation expense, net of tax, which the company expects to be approximately $1.3 million. Included in full year revenue estimate is $6.6 million to $6.8 million in sales of the new patient monitor.